← Browse by Condition
Medical Condition

pdac

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for pdac sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pdac Clinical Trials

How many clinical trials are currently recruiting for pdac?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for pdac, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pdac?
pdac research spans Phase 1 (4 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pdac clinical trial?
Eligibility criteria for pdac trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
3
Top Sponsors
Revolution Medicines, Inc. 1 trial
Anocca AB 1 trial
InxMed (Shanghai) Co., Ltd. 1 trial
Genfleet Therapeutics (Shanghai) Inc. 1 trial

Recruiting Clinical Trials

NCT07349537 Phase 1
Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Enrollment
574 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
View Trial →
NCT07145450 Phase 1, Phase 2
Recruiting

Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

Enrollment
96 pts
Location
Denmark, Germany, Ne...
Sponsor
Anocca AB
View Trial →
NCT07441174 Phase 1, Phase 2
Recruiting

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

Enrollment
92 pts
Location
China
Sponsor
InxMed (Shanghai) Co., Ltd.
View Trial →
NCT07259590 Phase 1, Phase 2
Recruiting

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Enrollment
126 pts
Location
China
Sponsor
Genfleet Therapeutics (Shangha...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology